Trial Library has secured $10 million in Series A financing, co‑led by SemperVirens Venture Capital and Next Ventures, to expand its AI‑enabled platform aimed at improving access to oncology clinical trials in community-based settings, according to Health IT Media.
Funding Round Details
The Series A round was co‑led by SemperVirens Venture Capital and Next Ventures and included participation from Sanofi Ventures, Civilization Ventures, How Women Invest, Overwater Ventures, and Lux Capital, as reported by Health IT Media.
Trial Library currently operates across more than 320 clinics and over 1,500 providers across the U.S. It plans to use the new capital to further expand its network and strengthen partnerships with payers such as self‑insured employers and health plans, according to Health IT Media.
Pulse2 reported that the company aims to broaden clinical trial access in community healthcare settings, noting that while approximately 85% of cancer patients receive treatment in community settings, trials have historically centered in academic centers.
Platform and Mission
Pulse2 describes Trial Library’s platform as AI‑enabled, engaging providers to identify eligible patients and guide them throughout the trial process. The company’s goal is to normalize clinical research as part of standard care in community settings.
Health IT Media adds that Trial Library has raised a total of $15 million to date, with this Series A round contributing $10 million.
Analysis
This funding round reflects growing investor confidence in decentralized, AI‑driven approaches to clinical trial recruitment. By focusing on community settings, Trial Library addresses a longstanding gap in trial access, especially for patients outside major academic institutions.
The involvement of diverse investors, including How Women Invest, may signal a broader industry interest in both gender diversity in funding and inclusive healthcare models.
Conclusion
Trial Library’s Series A funding round demonstrates momentum behind expanding equitable clinical trial access beyond academic centers. With new capital and a growing clinic network, the company is poised to advance its mission of embedding clinical research into routine community care.